L-Serine potentiates fluoroquinolone activity against Escherichia coli by enhancing endogenous reactive oxygen species production

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2192-2199

  Duan, Xiangke ^a   Huang, Xue ^a   Wang, Xiaoyu ^a   Yan, Shuangquan ^a   Guo, Siyao ^a   Abdalla, Abualgasim Elgaili ^a,b   Huang, Changwu ^c   Xie, Jianping ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b OMDURMAN ISLAMIC UNIVERSITY   (Sudan)

^c The Fifth People's Hospital of Chongqing   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FERROZINE; IRON; IRON SULFUR PROTEIN; MOXIFLOXACIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OFLOXACIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SERINE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CELL LEVEL; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ESCHERICHIA COLI; GROWTH CURVE; IN VITRO STUDY; NONHUMAN; OXIDATIVE STRESS; CHEMISTRY; CYTOSOL; DRUG EFFECTS; DRUG INTERACTION;

ANTI-BACTERIAL AGENTS; CYTOSOL; DRUG INTERACTIONS; ESCHERICHIA COLI; FLUOROQUINOLONES; IRON; NAD; REACTIVE OXYGEN SPECIES; SERINE;

EID: 84982218397     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw114     Document Type: Article

References (61)

1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009; 360: 439-43.
2. Piddock LJV. The crisis of no new antibiotics-what is the way forward? Lancet Infect Dis 2012; 12: 249-53.
3. Cottarel G, Wierzbowski J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol 2007; 25: 547-55.
4. Rowley D. Inhibition of E. coli strains by amino-acids. Nature 1953; 171: 80-1.
5. Amos H, Cohen G. Amino acid utilization in bacterial growth. 2. A study of threonine-isoleucine relationships in mutants of Escherichia coli. Biochem J 1954; 57: 338.
6. Saito KTK, Yamada K. Growth inhibition by L-serine in Bacillus subtilis MF920. Nippon Shokuhin Kagaku Gakkaishi (Jpn J Food Chem) 2001; 8: 117-20 (in Japanese).
7. Hama H, Sumita Y, Kakutani Y et al. Target of serine inhibition in Escherichia coli. Biochem Biophys Res Commun 1990; 168: 1211-6.
8. Hama H, Kayahara T, Tsuda M et al. Inhibition of homoserine dehydrogenase I by L-serine in Escherichia coli. J Biochem 1991; 109: 604-8.
9. Hama H, Kayahara T, Ogawa W et al. Enhancement of serine-sensitivity by a gene encoding rhodanese-like protein in Escherichia coli. J Biochem 1994; 115: 1135-40.
10. Shan Y, Lazinski D, Rowe S et al. Genetic basis of persister tolerance to aminoglycosides in Escherichia coli. mBio 2015; 6: e00078-15.
11. Jacoby GA, Hooper DC. Review of the quinolone family. In: Dougherty TJ, Pucci MJ, eds. Antibiotic Discovery and Development. NewYork: Springer, 2012; 119-46.
12. Drlica K, Malik M, Kerns RJ et al. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008; 52: 385-92.
13. Drlica K, Zhao XL. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-92.
14. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003; 51: 29-35.
15. Wang XH, Zhao XL, Malik M et al. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 2010; 65: 520-4.
16. Ferrándiz M, Martín-Galiano A, Arnanz C et al. Reactive oxygen species contribute to the bactericidal effects of the fluoroquinolone moxifloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2016; 60: 409-17.
17. Dwyer DJ, Kohanski MA, Hayete B et al. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol 2007; 3: 91.
18. Keren I, Wu Y, Inocencio J et al. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 2013; 339: 1213-6.
19. Liu Y, Imlay JA. Cell death from antibiotics without the involvement of reactive oxygen species. Science 2013; 339: 1210-3.
20. Voziyan P, Yazlovitskaya E. Reactive oxygen species. J Bioequiv Availab 2014; 6: e57.
21. Imlay JA. Pathways of oxidative damage. Annu Rev Microbiol 2003; 57: 395-418.
22. Brynildsen MP, Winkler JA, Spina CS et al. Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat Biotechnol 2013; 31: 160-5.
23. Riemer J, Hoepken HH, Czerwinska H et al. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 2004; 331: 370-5.
24. Su H, Newman EB. A novel L-serine deaminase activity in Escherichia coli K-12. J Bacteriol 1991; 173: 2473-80.
25. Shao Z, Newman EB. Sequencing and characterization of the sdaB gene from Escherichia coli K-12. Eur J Biochem 1993; 212: 777-84.
26. Burman JD, Harris RL, Hauton KA et al. The iron-sulfur cluster in the L-serine dehydratase TdcG from Escherichia coli is required for enzyme activity. FEBS Lett 2004; 576: 442-4.
27. Cicchillo RM, Baker MA, Schnitzer EJ et al. Escherichia coli L-serine deaminase requires a [4Fe-4S] cluster in catalysis. J Biol Chem 2004; 279: 32418-25.
28. Jurtshuk P. Bacterial metabolism. In: Baron S, Jennings MP, eds. Medical Microbiology, 3rd edn. New York: Churchill Livingstone, 1991; 69-89.
29. Cronan JE Jr, Laporte D. Tricarboxylic acid cycle and glyoxylate bypass. EcoSal Plus 2006; doi:10.1128/ecosalplus.3.5.2.
30. Imlay JA, Fridovich I. Assay of metabolic superoxide production in Escherichia coli. J Biol Chem 1991; 266: 6957-65.
31. Imlay JA, Fridovich I. Superoxide production by respiring membranes of Escherichia coli. Free Radic Res Commun 1991; 12-3: 59-66.
32. Kohanski MA, Dwyer DJ, Hayete B et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130: 797-810.
33. Keyer K, Imlay JA. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci USA 1996; 93: 13635-40.
34. Abed DA, Goldstein M, Albanyan H et al. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B 2015; 5: 285-99.
35. Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Lond A 1934; 147: 332-51.
36. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10: 9-17.
37. Goswami M, Mangoli S, Jawali N. Involvement of reactive oxygen species in the action of ciprofloxacin against Escherichia coli. Antimicrob Agents Chemother 2006; 50: 949-54.
38. Becerra M, Albesa I. Oxidative stress induced by ciprofloxacin in Staphylococcus aureus. Biochem Biophys Res Commun 2002; 297: 1003-7.
39. Li Q, Peng S, Sheng Z et al. Ofloxacin induces oxidative damage to joint chondrocytes of juvenile rabbits: excessive production of reactive oxygen species, lipid peroxidation and DNA damage. Eur J Pharmacol 2010; 626: 146-53.
40. Dwyer DJ, Kohanski MA, Collins JJ. Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol 2009; 12: 482-9.
41. Zhao X, Drlica K. Reactive oxygen species and the bacterial response to lethal stress. Curr Opin Microbiol 2014; 21: 1-6.
42. Zhao X, Hong Y, Drlica K. Moving forward with reactive oxygen species involvement in antimicrobial lethality. J Antimicrob Chemother 2015; 70: 639-42.
43. Cui Y, Zhao Y, Tian Y et al. The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. Biomaterials 2012; 33: 2327-33.
44. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007; 5: 48-56.
45. Gefen O, Balaban NQ. The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol Rev 2009; 33: 704-17.
46. Lewis K. Persister cells. Annu Rev Microbiol 2010; 64: 357-72.
47. Wolfson J, Hooper D, McHugh G et al. Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and β-lactam antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 1938-43.
48. Falla TJ, Chopra I. Joint tolerance to β-lactam and fluoroquinolone antibiotics in Escherichia coli results from overexpression of hipA. Antimicrob Agents Chemother 1998; 42: 3282-4.
49. Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr Opin Pharmacol 2012; 12: 551-5.
50. Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 2011; 14: 519-23.
51. Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol 2013; 31: 177-84.
52. Tuomanen E, Cozens R, Tosch W et al. The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 1986; 132: 1297-304.
53. Paramasivan C, Sulochana S, Kubendiran G et al. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic-and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 627-31.
54. Gilbert P, Collier PJ, Brown MR. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother 1990; 34: 1865-8.
55. Hammond RJ, Baron VO, Oravcova K et al. Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you? J Antimicrob Chemother 2015; 70: 2823-7.
56. Zeiler H-J, Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol 1984; 3: 339-43.
57. Kaldalu M, Mei R, Lewis K. Killing by ampicillin and ofloxacin induces overlapping changes in Escherichia coli transcription profile. Antimicrob Agents Chemother 2004; 48: 890-6.
58. Kim JS, Heo P, Yang TJ et al. Selective killing of bacterial persisters by a single chemical compound without affecting normal antibiotic-sensitive cells. Antimicrob Agents Chemother 2011; 55: 5380-3.
59. Dorr T, Vulic M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 2010; 8: e1000317.
60. Roveta S, Schito AM, Marchese A et al. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 2007; 30: 415-21.
61. Hu Y, Coates ARM, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung D 2008; 12: 69-73.